Many small pharma companies in India may shut down. They did not meet the deadline for upgrading facilities. This is as per new Good Manufacturing Practices. Only 1,700 out of 6,000 units submitted upgrade plans. Closures could lead to job losses. There are also concerns about potential drug shortages and price increases. The government may initiate...
Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India
Abbott and MSD Pharmaceuticals have partnered to distribute oral anti-diabetic medicines in India. Abbott will distribute MSD's sitagliptin, its combination sitagliptin/metformin, and the extended-release version, marketed as Januvia, Janumet, and Janumet XR. This collaboration aims to leverage Abbott's extensive reach to ensure continued access to...
Suraksha Diagnostics to invest Rs 200 cr to set up over 20 centres across east India
Suraksha Diagnostics plans a significant expansion. The company will invest Rs 200 crore. This investment will establish over 20 advanced imaging centers. These centers will be located across eastern India. The expansion aims to improve diagnostic services. It will focus on tier 2 and tier 3 cities. This initiative will enhance healthcare access in...
Glenmark gets five observations from USFDA for Monroe plant
Glenmark Pharmaceuticals announced that its Monroe, North Carolina manufacturing plant received a Form 483 with five observations from the USFDA following a GMP inspection conducted in June 2025. The company stated that the observations are procedural and don't involve data integrity issues. Glenmark is committed to addressing the concerns and will...
Torrent Pharma keen to break into big league
Torrent Pharma, currently seventh in India, is aimingto break into the top three drugmakers within five years through strategic acquisitions. Bolstered by consistent growth in the Indian market, the company plans further investments following past deals like Curatio Healthcare. Expansion includes doubling its medical representatives to 7,000 for better...
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030.
from Healthcare/Biotech-Industry-Economic...
Zydus Healthcare appoints Swati Dalal MD
Zydus Lifesciences Ltd. has appointed Swati Dalal as an additional director and Managing Director of its subsidiary, Zydus Healthcare Ltd., effective June 16, 2025, for a five-year term. Dalal brings over 30 years of experience, most recently serving as Managing Director of Abbott India Ltd. Her career includes leadership roles at Wockhardt Nutrition,...
Lupin inks pact with China's Sino Universal Pharmaceuticals for Tiotropium dry powder inhaler
Lupin Limited partners with Sino Universal Pharmaceuticals. They will commercialize Tiotropium dry powder inhaler in China. This inhaler treats Chronic Obstructive Pulmonary Disease. Sino Universal will seek regulatory approvals. Lupin will manufacture the product. This collaboration expands Lupin's presence in China. It aims to improve respiratory...
Online pharmacies could face stricter check-ups
Amid rising concerns over unverified prescriptions and a surge in online pharmacies, the government is intensifying regulation and scrutiny on platforms promising medicine delivery within minutes. Complaints regarding bypassed safeguards like age verification have prompted this action.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MY96ZRe
via...
Kirti Ganorkar: Why the veteran insider is the right dose for Sun Pharma
Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma gets eight observations from USFDA for Halol plant
Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. The USFDA conducted a Good Manufacturing Practices (GMP) inspection at the facility from June 2-13, 2025. The Form 483, issued at the inspection's conclusion, highlights conditions that may violate the Food, Drug,...
Delhi HC refuses to halt Sun Pharma’s Pruease tables sales over trademark row
The Delhi High Court has denied RSPL Health's petition to stop Sun Pharmaceutical Industries from selling Pruease tablets, a constipation relief medication. RSPL Health, which sells sanitary napkins under the trademark 'Pro-ease,' claimed trademark infringement. The court dismissed the plea, stating that the products have distinct trade channels and...
Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes...
Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea
Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial...
Pharma body opposes entry curbs on medical representatives, seeks rethink
The Indian Pharmaceutical Alliance (IPA) voices concerns over the government's ban on medical representatives in central hospitals, arguing it hinders knowledge dissemination and patient care. IPA urges a structured engagement model, citing potential impacts on pharmaceutical growth, job losses, and the introduction of new therapies. They emphasize...
Niti Aayog may prescribe major revamp of AIIMS Delhi
Niti Aayog is expected to propose a major overhaul of AIIMS Delhi, including expanding its clinical services across the NCR to ease infrastructure pressure and allow doctors to focus more on research. A VK Paul-led committee is preparing a blueprint to reform AIIMS to global standards, with plans to utilize other government or private hospital spaces...
Glenmark to launch DCGI-approved cancer drug in India
Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings,...
Advent International to acquire stake in Felix Pharmaceuticals
Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support...
KKR-backed IVI to buy ART Fertility clinics for $450 million
IVI RMA Global, backed by KKR, is poised to acquire ART Fertility Clinics for $400-450 million, marking a significant expansion into India's burgeoning IVF market. This acquisition will add India to IVI RMA's global presence. The deal highlights the ongoing consolidation in the Indian IVF sector, driven by increasing infertility rates and private equity...
One cough too many: India's TB fight isn't quite there yet
Despite India's commitment to eliminate TB by 2025, the nation grapples with a significant burden of drug-resistant cases and underreporting. Stories like Anushka's highlight the challenges in accessing effective treatments and the critical need for improved diagnostics, funding, and equitable care.
from Healthcare/Biotech-Industry-Economic Times...
API prices fall sharply, easing pressure on India's pharmaceutical industry
India's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and aggressive pricing strategies from Chinese suppliers. Increased domestic API production, driven by government incentives and reduced raw material costs, further contribute to the decline. This trend is expected to...
Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.
from Healthcare/Biotech-Industry-Economic...
Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe
Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via...
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization...
Avoid crowded places: Union Health Ministry amid surge in COVID-19 cases
India faces a rise in Covid-19 cases. The Health Ministry advises avoiding crowds and maintaining hygiene. Technical reviews and preparedness measures are underway. Surveillance for ILI and SARI has increased. Testing and genome sequencing are in progress. States are instructed to ensure resource availability. Mock drills are planned to assess oxygen...
Murae Organisor board to consider bonus issue, dividend payout next week
Murae Organisor's board will convene on June 13 to deliberate on a bonus issue of equity shares and dividend payment for FY25. The company is also eyeing strategic business expansion, including investments in agro and distillery sectors. Furthermore, Murae Organisor has set June 11 as the record date for its 1:2 stock split, reporting a revenue of...
IIT Delhi and AIIMS Delhi to establish AI centre for healthcare with Rs 330 crore grant
IIT Delhi and AIIMS Delhi have partnered to establish a Centre of Excellence for Artificial Intelligence in Healthcare (AI-CoE), supported by a ₹330 crore government grant. The centre aims to develop AI-driven solutions to enhance healthcare access and delivery across India, focusing on key national health programs. This initiative seeks to improve...
Ujjain to host Spiritual & Wellness Summit, showcasing India’s holistic future
Ujjain is set to host the Spiritual & Wellness Summit on June 5, drawing spiritual leaders, wellness experts, and policymakers. Madhya Pradesh Chief Minister Mohan Yadav will inaugurate the summit, highlighting Ujjain's spiritual legacy. Panel discussions will explore collaborative frameworks harmonizing traditional health systems with modern wellness...
Biocon gets CDSCO nod for generic diabetes medication
Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly...
Medical representatives banned from visiting doctors in govt hospitals
The central government has banned medical representatives from directly meeting doctors in government hospitals to curb unethical practices and potential conflicts of interest. This decision aims to ensure doctors dedicate their time to patient care rather than promotional activities. The government encourages digital communication for sharing treatment...
Glenmark’s blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.
from Healthcare/Biotech-Industry-Economic...
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights...
Apollo Hospitals plans to sell maternity care arm
Apollo Hospitals Enterprises is planning to divest its maternity and infant care chain, Apollo Cradle and Children's Hospital (ACCHL). Allegro Capital has been appointed to find a buyer for ACCHL, with an estimated valuation of ₹1,000-1,200 crore. The sale process is underway, targeting leading private equity funds amidst a growing mother and child...
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D...
US FDA approves Moderna's next-gen COVID vaccine for adults 65 or older
Moderna's updated COVID-19 vaccine has received FDA approval for individuals aged 65 and older, marking the first endorsement under stricter regulatory guidelines. The vaccine is also authorized for those between 12 and 64 who have underlying health conditions that increase their risk. This approval signifies a step forward in protecting vulnerable...
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is...
Daiichi comments continue to damage interests: IHH Unit
Northern TK Venture, a subsidiary of IHH Healthcare, has increased its legal claim against Daiichi Sankyo. The claim is now for ₹11,800 crore. NTK alleges Daiichi Sankyo blocked its 2018 open offer for Fortis Healthcare. Daiichi Sankyo denies these claims. NTK seeks damages and an injunction against Daiichi Sankyo's statements. The next court hearing...
Fortis Open Offer: Daiichi Sankyo's 'misleading' statements continue to damage interests, says NTK
IHH Healthcare's subsidiary, NTK, accuses Daiichi Sankyo of damaging its interests through misleading statements regarding the Fortis Healthcare open offer. NTK has increased its damages claim against Daiichi Sankyo to JPY 200 billion, alleging obstruction of the open offer's completion.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gBNxZ4I
via...
Flush expired, unused opioids down the toilet, says regulator
Drug regulatory authority mandates disposal of unused opioid drugs and painkillers. This action aims to prevent misuse and health risks. Central Drugs Standard Control Organisation has listed 17 harmful medicines for disposal. Some drugs should be flushed, while others can be collected through 'drug take back' programs. Unscientific disposal causes...
India gears up to reboot ICU standards, fix doctor drain, and cash in on global med travel
India is developing a structured critical care framework to bridge infrastructure and human resource gaps. Led by NITI Aayog, the initiative will define resource allocation, patient prioritization, and standards for critical care units nationwide. This aims to improve domestic healthcare and attract medical tourists, addressing current imbalances and...
Novartis offers payment plan for high-cost heart medicine
Novartis introduces a financing scheme with Pine Labs for its cholesterol-lowering drug, Sybrava (inclisiran), in India, aiming to broaden access by offering zero-interest EMI options. This strategy addresses the drug's high cost, previously ₹1.2 lakh per injection, and involves partnerships with Mankind Pharma, JB Pharma, and Lupin to expand market...
Quadria's third fund nets $1 billion, to deploy 60% in India
Quadria Capital, an Asia healthcare-focused private equity firm, has successfully raised $1.07 billion for its third fund, surpassing its initial $800 million target. The oversubscribed fund will allocate approximately 60% of its capital to India, with the remainder invested in ASEAN countries. This fund also marks the first time Quadria Capital has...
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Lupin, an Indian drug maker, partners with SteinCares. The agreement focuses on ranibizumab's commercialisation. Latin America, excluding Mexico and Argentina, is the target. SteinCares will handle regulatory aspects. Lupin will manufacture the biosimilar drug. This collaboration aims to improve retinal care access.
from Healthcare/Biotech-Industry-Economic...
VC funding, influencers power India’s health supplements craze amid lingering safety concerns
Fast forward to 2025, and a whole new market has emerged — gummies to enhance your hair health, powders to boost collagen, liquid for gut, pills for women’s perimenopause hormonal imbalance, magnesium tablets for better sleep, testosterone boosters, capsules with calming properties and vegan versions of all these.
from Healthcare/Biotech-Industry-Economic...
Dr Reddy's gets 2 observations from USFDA for Telangana API plant
Dr. Reddy's Laboratories received a Form 483 with two observations following a GMP inspection by the USFDA at its API manufacturing plant (CTO-5) in Miryalaguda, Telangana. The inspection, conducted from May 19 to May 24, 2025, identified potential violations of the Food Drug and Cosmetic Act. The company plans to address the concerns within the given...
China’s India Headache: The growing pharmaceutical industry
Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring trend and a desire to diversify from China. These companies are investing in advanced technologies and specialized capabilities, particularly in biologics and complex chemistry, to capture a larger share of the global market.
from...
Venus Remedies gets Ukrainian GMP renewal certification
Venus Remedies has received renewed GMP certification from Ukraine. This certification applies to its Baddi facility. It covers cephalosporin, non-cephalosporin, and oncology production lines. The company aims to strengthen its presence in Ukraine and PIC/S markets. This will facilitate international growth. The Ukrainian pharmaceutical market is expected...
Waive risk-based inspections, urges MSME pharma body
Laghu Udyog Bharati requests the government to waive risk-based inspections for companies upgrading their facilities. The association seeks an extension for Schedule M implementation for smaller firms. Concerns arise over inspections being conducted like raids. LUB highlights the role of MSMEs in supplying medicines during Covid. They request special...
Sun Pharma to invest $25 mn in Pharmazz Inc; raises stake to 22.7 pc
Sun Pharmaceutical Industries Ltd will invest up to USD 25 million in Pharmazz Inc, increasing its stake to 22.7%. This investment triggers the conversion of a previous agreement. Sun Pharma gains an option to negotiate licensing of Sovateltide for developed markets and already holds exclusive rights for emerging markets. Pharmazz is developing drugs...
Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
Alembic Pharmaceuticals announced that it has secured final approval from the USFDA for its generic amlodipine and atorvastatin tablets, used for treating hypertension. The approval covers multiple strengths of the tablets, therapeutically equivalent to Pharmacia and Upjohn Co LLC's Caduet. With this approval, Alembic now has a cumulative total of...
Zydus working on single pen device for adjustable Semaglutide doses
Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both diabetes and obesity. Clinical trials are underway in India. Zydus plans a day 1 launch in India. They will explore partnerships for emerging markets. The device aims to improve patient convenience. Some companies...
Many MSME pharma firms making substandard drugs, CDSCO data shows
Data from the CDSCO reveals that numerous MSME pharmaceutical companies in India are producing substandard drugs, failing to meet safety standards. Inspections have uncovered issues with infrastructure, quality management, and manufacturing processes. A significant percentage of MSMEs have faced stop production orders due to these quality concerns,...
Neuberg, Star Imaging in joint venture to expand integrated diagnostics across Maharashtra
Neuberg Diagnostics and Star Imaging have partnered to expand integrated diagnostic centers across Maharashtra, aiming to unify radiology, pathology, wellness, and genomics for improved accuracy and faster diagnoses. This joint venture will establish a comprehensive, technologically advanced network, launching new centers in key cities like Pune and...
Bharat Biotech's cholera vaccine successfully completes Phase-III trials
Bharat Biotech's oral Cholera Vaccine, Hillchol, has successfully completed phase III clinical trials, demonstrating non-inferiority against Ogawa and Inaba serotypes in Indian adults and children. The study involved 1,800 participants across various age groups and ten clinical sites in India. With a production capacity of 200 million doses, Hillchol...
Aman Mehta appointed Managing Director of Torrent Pharma
Torrent Pharmaceuticals has appointed Aman Mehta, son of current chairman Samir Mehta, as Managing Director, effective August 1, 2025. This move marks the third-generation leadership taking charge, building upon the legacy of founder Uttambhai Nathalal Mehta. Aman's experience includes successful integration of acquisitions and strategic roles across...
IHH Healthcare increases damages claim against Daiichi Sankyo to Rs 11,800 cr over Fortis acquisition dispute
IHH Healthcare's indirect subsidiary, Northern TK Venture Pte Ltd, has significantly increased its damages claim against Daiichi Sankyo to approximately Rs 11,800 crore. This revision follows Daiichi Sankyo's alleged interference with IHH's bid to acquire a larger stake in Fortis back in 2018. The increased claim accounts for losses and reputational...
Domestic drug companies in a sweet spot as global players look beyond insulin
Indian drug companies are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin and more type 1 diabetes cases are helping them. Domestic companies accounted for 25% of the market. Multinational companies are shifting focus. This shift creates opportunities for Indian companies. Lupin...
India's orthopaedic and cardiac implant sector to touch $4.5-5 bn by FY28: Report
India's implant sector is set for significant growth. The orthopaedic and cardiac implant market may hit USD 5 billion by FY28. Domestic manufacturers are expanding rapidly. They are outpacing foreign companies. Government initiatives and healthcare improvements are fueling this surge. Zydus Lifesciences and Alkem Laboratories are investing in this...
Non-AI organisations won't make it to 2050, says Diogo Rau
Eli Lilly's Diogo Rau emphasizes the critical role of AI in the pharmaceutical industry's future, predicting that companies not investing in AI now may not survive by 2050. Rau highlights AI's potential in drug discovery, including designing proteins and identifying promising molecules. He notes the challenge of limited datasets and the importance...
Dr Reddy's gets 2 observations from USFDA for New York API plant
Dr. Reddy's Laboratories announced that the USFDA issued a Form 483 with two observations after a GMP inspection of its API manufacturing facility in Middleburgh, New York. The inspection, conducted between May 12-16, 2025, identified potential violations of the Food Drug and Cosmetic Act.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pfM1h8q
via...
'Irrational' fixed dose combos harmful, may face ban: Expert panel
Several personal care products containing ingredients like aloe vera, jojoba oil, and orange oil are likely to be banned in India. An expert committee has deemed these fixed-dose combinations (FDCs) as irrational and potentially harmful to human health.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8ofjYH2
via IFT...
Piramal Pharma to stay away from prescription business in India: Nandini Piramal
Piramal Pharma is not planning to re-enter the domestic prescription formulations business, according to chairperson Nandini Piramal. Instead, the company will focus on its consumer healthcare business, potentially acquiring OTC portfolios or brands, and explore targets in its global complex hospital generics business. Piramal Pharma will continue...
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
A report suggests Indian generic drug companies may not be affected by US President Donald Trump's order. The order aims to lower US prescription drug prices. It will match them to those of other developed nations. The 'Most-Favoured-Nation' price model will be introduced. This model will cover Medicare and Medicaid. The order may face legal challenges.
from...
Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran Shaw
Biocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity, aiming to improve profitability. The company is also considering a merger with its parent company as an alternative to an IPO due to market uncertainties.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iaU2g47
via...
Donald Trump’s order to lower prices may benefit generics, says Cipla CEO
Cipla anticipates that Donald Trump's order to lower US drug prices could favor generic drug companies like itself. The company reported a strong Q4 performance with a 30% increase in net profit. Cipla is optimistic about growth in India, particularly in the weight-loss drug market, and is exploring both organic and inorganic expansion opportunities.
from...
US govt order to have nil impact on Indian pharma players, says Cipla
Umang Vohra of Cipla says that the US order to lower drug costs will likely target branded drugs. He believes generic drug prices are already competitive. Vohra also states that potential US tariffs on pharmaceutical imports are not expected to significantly impact Cipla's business. He mentions that discussions between the US and Indian governments...
Lupin launches generic version of kidney disorder treatment drug in US
Lupin Ltd has launched generic Tolvaptan tablets in the US, after receiving USFDA approval. These tablets, with strengths of 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, are bioequivalent to Jynarque and indicated for slowing kidney function decline in adults with ADPKD. Lupin holds exclusive first-to-file status, granting them 180-day generic drug exclusivity.
from...
Trump drops the price bomb, Indian pharma may feel aftershock
President Trump's plan to lower US prescription drug prices by aligning them with other countries could impact Indian pharmaceutical companies, which heavily rely on the US market for revenue. While primarily targeting innovator drugmakers, the move may squeeze Indian generic firms, potentially leading to margin pressure and strategic adjustments.
from...
India has not accepted 'data exclusivity' demand by UK to protect generic drug firms
India has declined the UK's request for a 'data exclusivity' clause in their free trade agreement to safeguard its domestic generic drug industry. This decision mirrors a previous rejection of a similar demand from the EFTA bloc. The move aims to protect the flourishing generic drug sector, a key player in India's exports, from potential restrictions...
Trump's drug order sparks concern for India's pharma policy: GTRI
Donald Trump's "Most Favored Nation" pricing rule, aimed at significantly lowering U.S. drug prices, is expected to have global repercussions. The move could pressure pharmaceutical companies to seek higher revenues in markets like India, potentially impacting its pharmaceutical policies.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UXRAgN4
via...
Biocon plans $150-million capex in two years
Biocon plans a $150 million capital expenditure, allocating $100 million to biologics, primarily enhancing Malaysian capacities, and $50 million to generics. Fueled by strong generics growth and biosimilar progress, Q4 net profit surged 153%. The company launched key medications in the US and UK, focusing on peptide portfolios and biosimilars for future...
Dr. Reddy's eyes aspirational goal to be in top five in the Indian market
Dr. Reddy's Laboratories is prioritizing innovative product launches through strategic partnerships to achieve a 15-16% growth in the Indian market. The company's focus includes expanding its portfolio with new products, growing existing brands, and strengthening its consumer health segment. Recent successes include the launch of toripalimab and upcoming...
FDC recalls over 60,000 bottles of ophthalmic solution in US
FDC Ltd is recalling over 60,000 bottles of Timolol Maleate Ophthalmic Solution, a generic glaucoma medication, in the US market. The USFDA reported the recall, initiated on April 18, is due to a defective container issue where the bottle's spike was lodged in the nozzle, preventing solution dispensing.
from Healthcare/Biotech-Industry-Economic Times...
Zydus gets USFDA nod for generic drug to treat multiple sclerosis
Zydus Lifesciences has secured USFDA approval to market Glatiramer Acetate Injection, a generic version of Copaxone, for treating relapsing forms of Multiple Sclerosis. Developed with Chemi S.p.A. and manufactured in Europe, the drug addresses a market with USD 719 million in annual sales in the US. This approval highlights Zydus' dedication to providing...
Generic versions of key diabetic drug in market double in a month
Post patent expiry, numerous Indian companies launched generic versions of Empagliflozin. The market witnessed a surge in brands and players in April. This makes diabetes drugs more affordable for Indian patients. Prices have dropped significantly, increasing access. Doctors are optimistic about the future. More patent expirations will further benefit...
Mounjaro is now a heavyweight in weight-loss fight
Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections increased significantly in April. Doctors are observing its effectiveness and side effects on Indian patients. Obesity is prevalent in India. Affordability and tolerance are key factors. Studies suggest constipation is a common side...
Aster DM Healthcare to invest Rs 480 cr to set up new hospital in Bengaluru
Aster DM Healthcare will invest Rs 480 crore to establish a 430-bed multispecialty hospital in Sarjapur, Bengaluru. The hospital, spanning 4 lakh sq ft, will be developed in two phases, with 300 beds operational by the second half of FY27 and the remaining 130 beds by FY29.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PX0s9jY
via...
Trump's new executive orders may hit Indian Pharma exports, reshape global drug supply chains: Report
The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gEMCJw8
via IFT...
Trump's prescription: Indian drug units may face stricter check-ups
Following President Trump's executive order, the Indian pharmaceutical industry anticipates a surge in unannounced inspections by the US FDA, causing concerns about compliance and potential trade barriers. Experts suggest that companies should diversify their business and invest in innovation to mitigate risks associated with increased scrutiny and...
TPG to acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India
TPG Growth is set to acquire a 35% stake in SCHOTT Poonawalla from Serum Institute of India, with Novo Holdings co-investing. This deal aims to bolster the drug containment firm's growth in India and globally. Serum Institute will retain a minority stake, while SCHOTT Pharma remains the controlling stakeholder, leveraging TPG's healthcare expertise.
from...
Revised rules for biosimilar drugs enter the final stretch
The Indian government is refining biosimilar drug regulations, aligning with global standards to ensure stringent quality in research and manufacturing. These revised 'Guidelines on Similar Biologics' prioritize minimizing animal testing, advocating for in-vitro studies and the 3R principles (replace, reduce, refine). The aim is to balance regulatory...
Biocon Biologics secures multiple market access agreements in US for Yesintek
Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 million lives. Multiple formularies, including Express Scripts, Cigna, and UnitedHealthcare, will include Yesintek starting in 2025. This approval expands affordable treatment options for Crohn's disease, ulcerative colitis, plaque...
Manipal, IHH, EQT & others eye Sahyadri Hospitals in Rs 5,000 crore bidding war
Manipal Hospitals, IHH Healthcare, and Blackstone-owned Quality Care India are among the frontrunners vying for Sahyadri Hospitals, Maharashtra's largest hospital chain, with bids ranging from ₹4,500-5,000 crore. Ontario Teachers’ Pension Plan Board is divesting the chain amid a wave of PE-led consolidation in India's rapidly growing healthcare sector,...
Panel to take a call on doorstep medicine delivery
India's drug advisory body is considering the future of doorstep medicine delivery, initiated during the Covid-19 pandemic. The All-India Organisation of Chemists and Druggists is urging the government to withdraw the notification, alleging misuse by digital platforms and prioritizing profit over patient safety. A sub-committee will now examine the...
With weight-loss drugs, going under the knife may lose edge
The introduction of weight-loss medications like Mounjaro and Wegovy in India may lead to a decrease in bariatric surgeries as obese individuals with a BMI of 30-35 may opt for drugs first. While surgeries can result in 70-80% weight loss, drugs offer a less invasive option, though potentially less effective at 15-20%.
from Healthcare/Biotech-Industry-Economic...
Alembic gets USFDA nod for generic drug
Alembic Pharmaceuticals secured USFDA approval to market generic Ticagrelor tablets, 90 mg, aimed at preventing heart attack and stroke. They also received tentative approval for the 60 mg version. The approved drug is equivalent to AstraZeneca's Brilinta, with the 90 mg tablet having a market size of over USD 1 billion.
from Healthcare/Biotech-Industry-Economic...
Opioid Tapentadol may be put under Narcotics Act to curb its access
The government is planning to regulate Tapentadol under the Narcotic Drugs and Psychotropic Substances Act. This follows concerns about its misuse and exports to West Africa. The move aims to control its availability. The Narcotics Control Bureau and police will oversee its movement. Tapentadol is a pain management drug with limited alternative treatment...
Ranitidine ban deferred despite cancer concerns
Despite concerns about cancer-causing agents in Ranitidine and an expert panel's recommendation to suspend it, India's drug advisory body has decided to form another committee to investigate. Previous tests revealed that many Ranitidine samples contained unsafe levels of NDMA impurities. The ICMR has been asked to conduct a study to assess the drug's...
BDR Pharmaceuticals plans $100 mn expansion in the US with manufacturing buyouts
BDR Pharmaceuticals is set to broaden its presence in the US through acquisitions of manufacturing facilities, backed by a $100 million investment. Chairman Dharmesh Shah mentioned the company is evaluating potential units and expects a decision within months, funded by internal accruals.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cK9xTlR
via...
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India through share swap
Aster DM Healthcare has finalized the acquisition of a 5% stake in Quality Care India Ltd (QCIL) through a share swap with BCP Asia II TopCo IV Pte Ltd and Centella Mauritius Holdings Limited. This acquisition marks the initial phase of the strategic merger between Aster DM Healthcare and Quality Care India.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod for generic cholesterol lowering drug
Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, 750 mg, and 1,000 mg strengths. These tablets, produced in Ahmedabad, address elevated cholesterol and triglycerides, reducing the risk of myocardial infarction. The US market for these tablets has annual sales of USD 5.5 million,...
Max Healthcare lines up Rs 6,000 crore for expansion
Max Healthcare is set to invest ₹6,000 crore over the next three years to expand its network, aiming to reach 25 hospitals by 2025. The expansion includes new facilities in Saket, Nanavati, Mohali, and Gurugram, with a recent inauguration of a 300-bed hospital in Dwarka.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pnvJMtA
via I...
Max Healthcare Institute to invest Rs 6,000 cr to add 3,700 beds by 2028
Max Healthcare will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals. The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi, and upcoming facilities in Mohali, Mumbai, and Saket. The company remains open to acquisitions beyond its organic...
Medanta to invest Rs 500 cr to set up 400-bed hospital in Guwahati
Global Health, known for its Medanta hospitals, is set to invest approximately Rs 500 crore in establishing a 400-bed super speciality hospital in Guwahati, Assam. The board has approved the land purchase for Rs 30 crore. This initiative aims to enhance healthcare infrastructure, offering advanced medical care across 20 specialities to over 50 million...
Dr Reddy's to introduce Sanofi's novel drug in India
Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing lower respiratory tract disease in newborns caused by RSV. Dr. Reddy's will exclusively promote and distribute Beyfortus in India, with a launch expected in the second quarter of the current fiscal year, following regulatory...
Roche made over 100 times the cost of a medicine that it sold in India, calculations show; company defends itself
A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal muscular atrophy (SMA), potentially earning 115 times its clinical trial expenses. Knowledge Ecology International estimates trial costs at $50 million, while Roche's risdiplam revenue reached $5.8 billion. Roche defends its pricing,...
Get evergreening patent requests very often, these benefit select few cos: Piyush Goyal
Piyush Goyal stated that India frequently receives requests to extend pharmaceutical patents for minor modifications. He criticized this practice, known as 'evergreening,' for prioritizing corporate profits over global healthcare access. Goyal highlighted Ayushman Bharat scheme, providing free healthcare to over 620 million people. He emphasized India's...
Zydus gets 6 observations from USFDA for API unit
Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug...
SS Innovations International to list on US exchange Nasdaq
SS Innovations International, an Indian surgical robotics company, is set to list on the Nasdaq under the ticker 'SSII' on April 25. The company experienced substantial revenue growth, reaching $20.6 million in 2024, a 3.5-fold increase from the previous year.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MAwe3r7
via IFT...
Reckitt Benckiser's rare reflection: India a big growth driver
Reckitt Benckiser's CEO, Kris Licht, highlights India as a key growth driver, anticipating sustained strong volume growth alongside China. The company's success is fueled by strong organic performance in germ protection (Dettol) and intimate wellness (Durex). Reckitt's strategic alignment with India's public health goals, through initiatives like 'Dettol...
To speed up delivery, govt exempts orphan drugs from testing at ports
To ensure timely access to life-saving orphan drugs for patients, the government has exempted mandatory sampling and testing at port offices. The drug regulator will now release consignments based on a legal undertaking from the importer. This decision addresses challenges like small volumes and specialized testing needs, streamlining the process and...
Relief for pharma cos as Delhi HC says cough syrup ban applies prospectively
The Delhi High Court has provided relief to pharma companies like Glenmark Pharmaceuticals and Zuventus Healthcare, ruling that the ban on fixed-dose combinations for children under four will be applied prospectively. The court directed companies to issue advisories to doctors and publish notices in national newspapers, informing that the drugs should...
Delhi HC orders cough syrup makers to warn against use in children below 4, issue public notices
Glenmark and Zuventus Healthcare have approached the Delhi High Court against the Centre’s April 15 notification banning the use of certain cough syrups for children below four years of age. The companies argued that the order should not apply retrospectively.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7BHbMS1
via IFT...
Drugs panel considering proposal to rein in sale of OTC medicines to prevent misuse
India's drug advisory board is considering restricting over-the-counter medication sales to prevent misuse and ensure patient safety. The proposal limits OTC sales to 27 drugs, including antipyretics and painkillers, with dosage and quantity restrictions. The board aims to increase accessibility while ensuring patient safety by excluding several currently...
Aurobindo Pharma arm gets USFDA nod for generic blood cancer drug
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd, has secured USFDA approval to produce and sell generic Dasatinib tablets, used for treating specific bone marrow and blood cancers. The approved tablets, available in multiple strengths, are therapeutically equivalent to Bristol-Myers Squibb's Sprycel. Launch is anticipated in Q1FY26, targeting...
Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton Bharat
India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a 326% surge in values for Q1 2025. Despite a slight quarterly dip due to macroeconomic factors, high-value deals are on the rise, particularly in M&A and PE activity, signaling confidence in scalable models and...
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply...
Dr Reddy's, Lupin recall products in US due to labelling, manufacturing errors: USFDA
Dr. Reddy's Laboratories and Lupin are recalling products in the US due to labeling and manufacturing issues. Dr. Reddy's is recalling an antiepileptic drug due to a labeling mix-up, where infusion bags were incorrectly labeled. Lupin Pharmaceuticals is recalling an antidepressant medication due to failed impurity specifications. The USFDA has classified...
India faces a silent cervical cancer crisis: Every 8 minutes, a woman dies, but HPV vaccine and early screening could prevent it
The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve prevention and treatment in India. The organisation emphasised the importance of indigenous HPV tests and vaccines in cancer screening, alongside strengthening diagnostic infrastructure. Key recommendations include early detection,...
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become...
Russia-Ukraine war: Indian pharma firm caught in crossfire, lobby seeks PM Modi’s help
An Indian pharmaceutical company, Kusum Healthcare, operating in Ukraine, suffered significant damages after a warehouse was reportedly struck by a missile, prompting the Federation of Pharma Entrepreneurs to seek Prime Minister Modi's intervention.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kKe1D3p
via IFT...
Shivinder Mohan Singh moves NCLT, files plea for personal insolvency
Shivinder Mohan Singh, the former Fortis Healthcare promoter, has sought personal insolvency before the NCLT, citing liabilities exceeding assets. Facing a Rs 3,500 crore recovery to Daiichi Sankyo, Singh's assets are largely attached or devalued due to litigation and mismanagement within RHC Holding.
from Healthcare/Biotech-Industry-Economic Times...
Pharmacists seek clarity on banned cough syrup stock
Pharmacists are seeking clarification from the DCGI regarding the handling of recently banned cough syrups for children under four, specifically concerning existing stocks and prescriptions. The IPA has requested guidance on whether to return stocks or sell them until depleted, and if prescriptions for young children can be dispensed. The industry...
Centre pushes for 'one nation, one swap transplant' system to boost kidney donations
India is set to promote kidney swap transplants nationwide, aiming to increase transplant numbers by up to 15%. Following a directive from NOTTO, states and union territories are encouraged to implement swap transplants, a practice already recognized but underutilized. The initiative includes a standardized document list and the potential creation...
Yoga vs Strengthening exercises: Which is better for knee osteoarthritis? Study reveals surprising results
A recent study indicates yoga is as effective as strengthening exercises for managing knee osteoarthritis, offering improvements in pain, quality of life, and depression. Experts highlight yoga's comprehensive approach, addressing mental health, balance, and joint mobility. Both yoga and resistance training achieve similar physiological goals through...
US tariff chaos, global headwinds hit pharma GCC hiring in India
Uncertainty surrounding US tariffs and global economic headwinds has tempered hiring in India's pharmaceutical and healthcare GCCs. Experts predict a 6-7% reduction in net talent addition this fiscal year as companies adopt a cautious approach. Despite this temporary slowdown, India remains a vital hub for R&D, with long-term growth prospects fueled...
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially...
Health ministry in talks to shield India’s pharma industry amid impending tariffs from team Trump
India's health ministry is actively exploring strategies to protect its pharmaceutical industry from potential US tariffs. Discussions involve a fixed tariff regime and waiving import tariffs on US pharma products. The US is also raising concerns about nutraceutical imports, prompting India to consider regulatory changes, potentially impacting the...
Divi's Lab inks supply pact with global pharmaceutical entity
Divi's Laboratories announced a long-term supply agreement with a global pharmaceutical company, focusing on manufacturing and supplying advanced intermediates. The company anticipates significant revenue generation from this partnership.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KBMRzNm
via IFT...
Govt bans select cough syrups for kids below 4 years
The government has prohibited cough syrups containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four due to safety concerns. Drug regulators are mandating manufacturers to include explicit warnings on labels and packaging. This decision follows recommendations from India's apex drug body after examining the fixed-dose...
Alembic Pharma gets USFDA nod for generic drug
Alembic Pharmaceuticals has received the United States Food and Drug Administration approval. The approval allows them to market Carbamazepine tablets in the US. This medication is a generic version of Tegretol Tablets. Carbamazepine tablets are anticonvulsants. They also treat pain from trigeminal neuralgia. The market size for these tablets is estimated...
Assam govt plans to transform GMCH into one of India's largest hospitals
Assam Chief Minister Himanta Biswa Sarma is undertaking steps to transform Gauhati Medical College and Hospital into one of India's largest. The upcoming Mother and Child Care Hospital on GMCH premises will offer specialized pediatric care with 800 beds.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYoetgL
via IFT...
Trump’s executive order on drug pricing could be a booster for Indian pharma industry
Donald Trump's healthcare revamp, emphasizing generics and biosimilars, could boost Indian drug makers, who already supply 40% of US generic imports. While the move aims to lower drug costs for Americans, potential tariffs on pharma imports create uncertainty.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LtGwUZb
via IFT...
In major development in pharma, halt order enforced on production and sale of 35 fixed-dose combination drugs
India's drug regulator, CDSCO, has ordered a halt to the production, sale, and distribution of 35 fixed-dose combination (FDC) drugs due to safety concerns. These drugs, including pain relievers and diabetes medications, lacked proper evaluation before approval. The CDSCO has directed state and Union territory regulators to reassess approval procedures,...
Mercury soars, and so do sales of rehydration drinks in India
India is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in March, leading the oral electrolyte market's growth. Doctors are reporting an increase in digestive disorder cases, further fueling the need for rehydration solutions as temperatures rise and waterborne diseases become...
AstraZeneca Pharma India surrenders marketing authorisation of prostate cancer drug
AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib (Lynparza) 100mg and 150mg in India, citing commercial reasons. The company clarified that the drug was never marketed in India since receiving approval in November 2023 and that the decision is unrelated to safety or efficacy concerns.
from...
Biocon Biologics secures market entry for Yesafili in US
Biocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili, its biosimilar to Eylea. The agreement allows Biocon Biologics to launch Yesafili in the US by the second half of 2026, or earlier under certain conditions. Yesafili, already approved by the USFDA, is intended...
Sweet Surrender: Sanofi puts star insulin brand Lantus up for sale, eyes Rs 2,000 crore from Indian pharma giants
Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licensing agreement remains a possibility. The asking price has been reduced to ₹2,000 crore due to declining sales and government price cuts. Despite newer insulin options, Lantus remains a market leader in India's growing...
Pharma companies may feel heat of US tariffs on China
India's pharmaceutical industry is bracing for potential disruptions due to US tariffs on Chinese goods. Experts warn that China may increase prices for key pharmaceutical ingredients exported to India to offset tariff costs. With India heavily reliant on China for APIs and intermediates, this could lead to higher medicine production costs.
from Healthcare/Biotech-Industry-Economic...
'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claim
Dr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the company aimed to cut manpower expenses by 25%, prompting high-salaried employees, including those earning over ₹1 crore annually, to resign. Voluntary retirement was also reportedly offered to R&D employees aged...
Dr Reddy’s slashing jobs to cut costs by 25%; asks several Rs 1 crore+ earners to resign
Dr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, including those earning over ₹1 crore annually, are being asked to resign. The R&D division is offering voluntary retirement to employees aged 50–55. Some divisions, like digital therapeutics, may face shutdowns or...
India's healthcare expenditure expected to surge from 3.3% to 5% of its GDP by 2030: CareEdge
India’s healthcare spending is projected to rise from 3.3% to 5% of GDP by 2030, according to a CareEdge report. The sector is poised for major transformation driven by investments, government initiatives, and demographic shifts.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ShcUkJe
via IFT...
Glenmark, Sun Pharma, Zydus recall products in US
Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the USFDA. Glenmark is recalling over 25 products, while Sun Pharma is recalling Gabapentin capsules due to cross-contamination. Zydus is recalling chlorproMAZINE Hydrochloride Tablets due to an impurity exceeding the...
Healthcare investors go for full-body check-up: Forensic due diligence rise as sector faces scrutiny
Investors are increasingly scrutinizing India's healthcare sector, including pharma companies and hospitals, due to concerns about potential malpractices and regulatory scrutiny. They are conducting in-depth due diligence, examining doctor-management relationships, referral practices, and the appropriateness of treatments. This heightened scrutiny...
Any tariffs on pharma sector would be counterproductive for Americans: Wockhardt Chairman Habib Khorakiwala
Wockhardt Chairman Habib Khorakiwala warns that potential US tariffs on pharmaceutical products would harm Americans. He highlights India's crucial role in supplying 40% of US prescription drugs at reasonable prices. Imposing tariffs would increase healthcare costs for Americans, given the lengthy FDA approval process and higher manufacturing and research...
Weight is over! Pharma companies race to make weight-loss drug semaglutide
Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic versions of Novo Nordisk's Wegovy and Ozempic as patents expire. These companies are developing novel technologies and aligning capacities for delivery pens, targeting both the Indian market and exports.
from Healthcare/Biotech-Industry-Economic...
USFDA issues Form 483 with 11 observations to Raleigh plant of Aurobindo Pharma arm
Aurobindo Pharma Ltd announced that the USFDA issued a Form 483 with 11 observations following an inspection of its Aurolife Pharma LLC's Raleigh plant in North Carolina. The company stated that the observations are procedural and it will respond with corrective actions. Aurobindo Pharma anticipates no significant impact on its operations or supplies...
Morepen to hire 1,000 medical representatives to strengthen formulations biz
Morepen Laboratories plans to significantly expand its medical representative team, adding over 1,000 members in the next three years, with 200 joining in FY26. This strategic move aims to bolster its formulations business and capture a larger share of the growing Indian pharmaceutical market, targeting Rs 1,000 crore in five years.
from Healthcare/Biotech-Industry-Economic...
Cipla gets USFDA nod for generic cancer drug
Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable suspension (100 mg/vial). This medication is indicated for treating metastatic breast cancer, non-small cell lung cancer, and pancreatic adenocarcinoma.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hv3QJnr
via...
Tariff risks cloud near-term pharma deals outlook: Rothschild's Stefano Beschi
Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u4w5GE3
via...
US court lifts restrictions on Sun Pharma launching autoimmune disorder drug
Sun Pharmaceutical Industries Ltd announced that a US court has ruled in its favour, immediately vacating a preliminary injunction that restricted the launch of LEQSELVI, a drug for treating autoimmune-related hair loss. This decision follows a patent infringement litigation with Incyte Corporation.
from Healthcare/Biotech-Industry-Economic Times...
Natco to sell rare spinal disease drug Risdiplam for ₹15,900
Each bottle of Risdiplam lasts around 12 days and that will take the cost to roughly ₹30,000 per month for the patient. Sources said Roche sells Risdiplam on a discounted basis or one bottle free for each bottle purchased.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lyOqN4
via IFT...
ZIM Labs inks pact with Globalpharma Co to commercialise oral thin film products
ZIM Laboratories Ltd has entered into a licensing and supply agreement with UAE-based Globalpharma Co. to commercialize oral thin film (OTF) products in the Gulf Cooperation Council (GCC) region. The agreement involves a dossier license, product supply, and technology know-how license for ZIM's proprietary 'ThinOral' OTF technology platform.
from...
Trump signals major tariff on pharma imports, Indian drugmakers could face impact
Donald Trump announced a forthcoming "major" tariff on pharmaceutical imports, aiming to incentivize drug companies to relocate operations to the U.S. He also stated he warned Taiwan Semiconductor Manufacturing Company (TSMC) about potential taxes if they didn't establish U.S. plants. Trump criticized the Biden administration's $6.6 billion grant to...
As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population,...
India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance,...
India’s anti-obesity drug market quadruples in five years on lifestyle disease surge
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025. Semaglutide pill Rybelsus is a key driver, capturing 69% of the market. The introduction of Mounjaro and upcoming launch of Wegovy are expected to further accelerate growth, driven by rising lifestyle diseases and increased willingness...
PE firms bet on small-town hospitals for a growth shot
Non-metro locations, such as Lucknow , Vizag, Jaipur, Cochin, Siliguri, Guwahati, Bhubaneswar and Patna, private equity investors believe, hold great growth potential in healthcare, in lockstep with an increasing affordability quotient in tier- 2 or 3 towns, and a greater availability of qualified doctors and specialists.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma launches medication for Erosive Esophagitis
Sun Pharmaceutical Industries has launched Fexuprazan tablets (40 mg) in India, branded as Fexuclue, to treat Erosive Esophagitis of all grades. Developed in collaboration with Daewoong Pharmaceutical, the drug showed over 95% healing efficacy in a Phase 3 study. This new treatment aims to meet the significant unmet medical need for this condition.
from...
Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform Eli Lilly's Mounjaro. Regulatory approval for Wegovy's cardiovascular benefits has been granted, pending final approval, allowing cardiologists to prescribe it.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pK6I3uf
via...
Govt plans capacity building activities for frontline workers of HPV vaccination
The Union Health Ministry plans to initiate capacity-building activities for frontline workers administering the HPV vaccine to girls aged 9-14 years to prevent cervical cancer. Following recommendations, the Ministry is finalizing strategies for this initiative. India accounts for a significant portion of global cervical cancer cases, with the vaccines...
Indians are quitting the safety net of health insurance; GST and high premiums are only part of the problem
Rising health insurance premiums and frequent claim rejections have led more Indians to drop their coverage. Despite the introduction of GST and government schemes, escalating costs leave many struggling to afford insurance, prompting calls for regulatory reforms to stabilize healthcare expenses.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vrU5ClS
via...
Kerala launches digital payment system, online services in govt hospitals
Kerala Health Minister Veena George announced the introduction of digital payment systems in 313 government hospitals to facilitate various service fee transactions. This system, part of the e-health initiative, employs POS devices from State Bank of India and Canara Bank, and includes capabilities such as the M-Health app and QR code-based ticket...
Now Pharma Inc looks for cure as Trump delivers dose of anxiety
US President Trump has announced that new tariffs on pharmaceuticals will be introduced soon, creating uncertainty for India's drug makers. Industry insiders are considering alternative markets to offset potential impacts, with companies preparing for any eventual developments.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T6McNyK
via...
T-Rx: Indian pharma majors breathe easy as US spares sector from reciprocal tariffs
Large Indian drug manufacturers experienced relief as President Trump's administration decided against imposing expected reciprocal tariffs on pharmaceuticals, which could have significantly impacted their earnings. Analysts deem future tariffs unlikely due to potential drug shortages and the influence of major pharma companies investing in the US.
from...
'Pharma's exemption from reciprocal tariffs underscores generic medicines' critical role globally'
The US Administration has exempted pharmaceuticals from reciprocal tariffs, highlighting the significance of affordable, life-saving generic medicines. The decision supports the vital trade partnership between India and the US, with Indian pharmaceutical companies supplying a substantial proportion of drugs to American residents and generating significant...
Big relief for India! Trump spares pharma from harsh tariffs
US President Trump has exempted India's pharmaceuticals from new reciprocal tariffs, benefiting the major export industry. This exemption highlights the significance of India's cost-effective generic medicines in US healthcare. The White House noted that removing trade barriers in other sectors could increase US exports by $5.3 billion annually.
from...
Fortis healthcare buys disputed Fortis trademark for Rs 200 crore
Fortis Healthcare has acquired the Fortis trademark from its former promoters, the Singh brothers, for Rs. 200 crore through a court-sanctioned auction. The trademark was involved in a litigation case with Japan's Daiichi Sankyo. Fortis Healthcare, now owned by IHH Healthcare, operates a network of 26 hospitals nationwide.
from Healthcare/Biotech-Industry-Economic...
Lupin acquires UK-based firm for 12.3 million pounds
Lupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to expand in the UK market with Renascience's products for infectious diseases, ear pain, and cardiovascular and renal treatment. This move supports Lupin's mission to provide accessible healthcare solutions.
from...
Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation. Despite strategic reviews and potential interest, fluctuations in stock prices and declining sales present hurdles in reaching a deal, with existing licensing agreements adding complexity.
from Healthcare/Biotech-Industry-Economic...
360 ONE, Claypond Capital get CCI nod to acquire stakes in API Holdings
Fair trade regulator CCI has approved 360 ONE and Claypond Capital Partners' joint proposal to acquire stakes in API Holdings. This transaction involves purchasing compulsorily convertible preference shares from MEMG Family Office LLP, indicating oversight to prevent unfair business practices and ensure fair competition.
from Healthcare/Biotech-Industry-Economic...
View: Will Trump's tariffs lift the veil on India's drug safety problem?
India’s pharmaceutical industry is facing potential tariffs imposed by President Trump, which could significantly impact exports, particularly to the US. High export dependence and questionable quality standards underscore the need for reform and improved regulation to maintain the industry’s reputation and market position.
from Healthcare/Biotech-Industry-Economic...
Ankura Hospitals secures Rs 165 cr funding from ADB
Ankura Hospitals has secured Rs 165 crore in funding from the Asian Development Bank. This strategic investment will enhance its pediatric, maternity, and gynecology services, enabling the Hyderabad-based chain to expand its facilities and strengthen its presence in key cities across India.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hmIAXlY
via...
KKR in talks to acquire US dental labs chain Leixir
Global investment firm KKR is in talks to acquire Leixir Dental Laboratory Group from Comvest Investment Partners at a valuation of $200-$250 million. Leixir, founded in 2013, offers various dental solutions and operates facilities in the US and India. Deloitte is advising on the sale process.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aeon5HM
via...
From AI to Telemedicine: Digital skills every healthcare professional should learn
Digital skills are crucial for healthcare professionals, with growing fields like telemedicine, AI-driven diagnostics, and data analytics. Continuous learning in electronic health records, cybersecurity, and emerging technologies like 3D printing and robotics is vital for those seeking to stay relevant and succeed in the evolving healthcare landscape.
from...
Eli Lilly working on a heart drug that may benefit Indians: CEO David Ricks
Eli Lilly is developing a groundbreaking drug, lepodisiran, to combat high LPA cholesterol levels prevalent in South Asians, potentially reducing it by 85%-90%. With heart disease cases surging in India, this phase 3 trial drug promises significant cardiovascular benefits, requiring only once-a-year administration. It's crucial, given the rising heart...
47 drugs found 'not of standard quality' in February
The Central Drugs Laboratories identified 47 drug samples as 'not of standard quality' in February, while State Drugs Testing Laboratories found 56 similar samples. One drug from West Bengal was found spurious and made by an unauthorized manufacturer. Regular action is taken to remove such drugs from the market.
from Healthcare/Biotech-Industry-Economic...
Essential medicines will cost you a bit more from April 1
Beginning April 1, prices for essential drugs like painkillers, antibiotics, and anti-diabetic medicines will rise by 1.74%. The increase is based on the change in the wholesale price index. The pharmaceutical industry is pushing for higher price hikes to counterbalance increased input costs over recent years.
from Healthcare/Biotech-Industry-Economic...
Kedaara, TA Associates vie for minority stake in Sagent Pharma
Kedaara Capital and TA Associates are in talks to acquire a significant minority stake in Sagent Pharma, valued at $500-600 million. Investment amounts are estimated between $150-200 million. Originally acquired by Ravi Penmetsa's Ellimist Singapore, Sagent specializes in generic injectables for the US market.
from Healthcare/Biotech-Industry-Economic...
Donor aid cuts may undo years of progress in combating HIV: Study
US President Trump's decision to suspend USAID programmes and fund cuts by other countries could lead to 10.8 million new HIV infections and 2.9 million HIV-related deaths by 2030 in low-and-middle-income countries. Major donor funding cuts may reverse decades of progress against HIV/AIDS, especially in sub-Saharan Africa and among vulnerable populations.
from...
Delhi HC asks Natco Pharma to pause Risdiplam launch amid patent dispute
The Delhi High Court has ordered Natco Pharma to maintain status quo on the launch of Risdiplam until April 2. Roche, which holds the patent for the drug, sought an injunction to prevent Natco from manufacturing it in India. The court highlighted the public interest in making the drug affordable.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kI9mxiE
via...
Open to tie-ups in India for selling Mounjaro: Eli Lilly CEO David Ricks
Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, recently launched in India. Priced significantly lower than in the US, Mounjaro's introduction anticipates strong demand in the country with over 100 million obese and diabetic individuals.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly's goal is to reach everyone who needs obesity care: Global CEO David Ricks
Eli Lilly's CEO David Ricks discusses the launch of diabetes and anti-obesity drugs Mounjaro and Zepbound, focusing on expanding access in emerging markets. He highlights new weight-loss drugs and emphasizes the importance of partnerships, including with Indian tech companies and governments, for tackling chronic diseases and improving public health...
India develops its first indigenous MRI machine, to reduce treatment costs
India has developed its first indigenous MRI machine to be installed at AIIMS Delhi by October for trials, reducing dependency on imports by 80-85%. An MoU was signed with SAMEER for the installation. The Ministry of Electronics and Information Technology is spearheading this technological advancement aimed at achieving self-reliance in medical technology.
from...
Meghalaya’s Gnanamma Healthcare Centre transitions to near net-zero electricity health facility
Gnanamma Healthcare Centre in Guwahati celebrates its transition to a near net-zero electricity facility with a new 6.05kW solar plant and battery energy storage. This upgrade ensures reliable power, especially for critical services like vaccine storage and emergency care, reducing carbon emissions and setting an example for sustainable healthcare...
Delhi HC rejects Roche's plea to block Natco Pharma on Risdiplam patent
The Delhi High Court denied Roche's request to temporarily restrain Natco Pharma from producing its spinal muscular atrophy drug, citing public interest and high prices. Natco is required to maintain detailed financial records and may owe damages if Roche ultimately wins the case.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zsjncES
via...
Heartening news: Device made in India to help transplant patients
India plans to develop cost-effective left ventricular assist devices (LVADs) to aid end-stage heart failure patients while they wait for donor hearts. With an estimated 50,000 patients needing heart transplants annually but a severe shortage of donor hearts, indigenously made LVADs could reduce costs and increase foreign medical visitors. Development...
₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis
India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce weight-loss drugs in the market. The economic impact is enormous, and local generics are preparing to offer more affordable alternatives to combat this growing health issue.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1XhQp5n
via...
Bharat Biotech invests Rs 600 cr to expand into cell, gene therapies
As per Bharat Biotech, the facility will tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival. Work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia.
from Healthcare/Biotech-Industry-Economic...
Entero Healthcare launches HealthEdge programme for chemists
Entero Healthcare Solutions launched the 'HealthEdge' program to modernise retail pharmacies and improve efficiency for over 86,000 chemists. The company also acquired the Aayu Chemist app and Medcords platform, aimed at enhancing profits and customer engagement. Entero reported significant revenue and profit growth in FY 2025 Q3.
from Healthcare/Biotech-Industry-Economic...
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising obesity and diabetes rates, India presents a significant market opportunity for the U.S.-based company. Mounjaro is already marketed in the UK and Europe for both conditions and under the name Zepbound for obesity in the U.S.
from...
India has a chance to lead in health space amid Global North's funding cuts: Gates Foundation CEO Mark Suzman
Mark Suzman, CEO of the Gates Foundation, sees the current global funding challenges as an opportunity for India to lead, particularly in health and development. Amid funding cuts from the US, UK, and France, Suzman remains optimistic about mobilizing resources for life-saving initiatives, highlighting India's cost-effective innovations.
from Healthcare/Biotech-Industry-Economic...
Impose safeguard duties on medical devices: AiMeD
The Association of Indian Medical Device Industry (AiMeD) has requested the government to impose safeguard duties on 12 medical device categories to shield domestic manufacturers from cheap imports. AiMeD highlighted a significant increase in imports, notably in syringes and needles, primarily from China, the US, and Singapore.
from Healthcare/Biotech-Industry-Economic...
AI, teleconsultation, modern tech being used in treatment, diagnosis: Nadda
Health Minister JP Nadda emphasized the government's commitment to enhancing healthcare through policies incorporating AI for TB detection, modern cancer treatments, and mental health teleconsultation. The goal is to increase health expenditure to 2.5% of GDP, currently at 1.84%, showcasing substantial achievements in improving maternal and child mortality...
Health expenditure now at 1.84 pc of GDP, moving steadily to 2.5 pc: JP Nadda
Union Health Minister JP Nadda stated that the Indian government’s health expenditure has reached 1.84% of GDP, moving towards the 2.5% target by 2025. From 2013-14's Rs 38,000 crore, current health allocations are nearly Rs 1 lakh crore. The National Health Policy 2017 aims to increase healthcare funding, with 1.
from Healthcare/Biotech-Industry-Economic...
Zydus Lifesciences gets USFDA nod to produce prostate cancer treatment drug
Zydus Lifesciences Ltd has received final approval from the USFDA to manufacture 60 mg Apalutamide tablets for prostate cancer treatment. These tablets will be produced at their Ahmedabad facility. Apalutamide, an androgen receptor inhibitor, is intended for metastatic castration-sensitive prostate cancer and had annual sales of USD 1,099.8 million...
India weighs lower tariffs for US medical devices amid trade talks
The Indian government is considering lowering tariffs on US medical devices to mitigate potential US tariff threats on Indian exports. While this aims to ease trade tensions, industry experts express concerns about the impact on India's self-reliance. Stakeholders suggest reciprocal market access as Indian exporters face high regulatory barriers in...
Gene therapy for blood cancer shows 73 per cent response rate in clinical trials
Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low and middle-income countries, patients in whom 'B-cell' tumours continue to grow following a period of remission (relapse), or do not respond to treatment (refractory), suffer from poor outcomes due to an absence of effective therapies.
from...
AIIMS critically short of staff amid land & budgetary issues
AIIMS in New Delhi is experiencing severe staff shortages, with hundreds of vacant posts for doctors and faculty members. A parliamentary committee has urged the health ministry to offer competitive compensation and prioritize the filling of these positions. Additionally, the slow progress of AIIMS' expansion projects has been criticized.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma, Zydus recall products in US: USFDA report
Sun Pharma and Zydus Pharmaceuticals are recalling products in the US market due to manufacturing issues, according to the USFDA. Sun Pharma is recalling Morphine Sulfate tablets for failed dissolution specifications, while Zydus is recalling Nelarabine Injection for failed impurities/degradation specifications.
from Healthcare/Biotech-Industry-Economic...
Skin cream, nasal spray, and... blindness? AIIMS doctors warn steroids misuse could trigger silent vision loss
Frequent use of steroid-based treatments for respiratory issues, allergies, and skin conditions can heighten the risk of glaucoma. Experts at AIIMS stress the importance of regular eye check-ups for early detection. Lifelong care and awareness programs at the primary care level are essential for preserving vision.
from Healthcare/Biotech-Industry-Economic...
Struggling with dry eyes? Haldi's power-packed compound might be the relief you need
A study by AIIMS reveals that bio-enhanced curcumin, found in turmeric (haldi), effectively treats mild to moderate dry eye disease by improving tear stability and reducing inflammation. The clinical trial showed significant improvements in tear metrics and symptoms, suggesting a natural, side-effect-free alternative treatment.
from Healthcare/Biotech-Industry-Economic...
China’s biotech is redrawing the global pharma map; what India can learn
American biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. AstraZeneca signed a deal with CSPC Pharma for a cardiac treatment, while Merck signed a $2 billion deal with Hansoh Pharma. Indian drugmakers are also collaborating with Chinese rivals. Mankind Pharma partnered with...
Parliamentary panel flags brain drain from health dept, delay in filling vacancies in research posts
A parliamentary committee has raised concerns about unoccupied posts of scientists in the Department of Health Research and recommended stopping contractual appointments to prevent brain drain. The panel emphasized enhancing higher education and research infrastructure, improving standards of living, and offering competitive pay to retain Indian professionals.
from...